Breakthrough Treatment for Rare Eye Disease Shows Exceptional Results Elegrobart Achieves 54-63% Response Rates for Thyroid Eye Disease For patients suffering from thyroid eye disease — a rare but devastating condition that can cause vision problems and facial disfigurement — Viridian Therapeutics has announced breakthrough Phase 3 trial results that offer genuine